N/A
Completed N=235
The Support, Educate, Empower (SEE) Program
Source: ClinicalTrials.gov NCT04735653 ↗Enrolled (actual)
235
Serious AEs
0.0%
Results posted
Nov 2025
Primary outcomePrimary: Mean Percent Electronically Monitored Medication Adherence Over Six Months — 77.6; 58.0 percent adherence — p=<0.001
Summary
This study will test whether the Support, Educate, Empower (SEE) personalized Glaucoma Coaching Program improves eye drop medication adherence among glaucoma patients compared to enhanced standard care in a randomized controlled clinical trial. As a secondary outcome, the study will test whether glaucoma related distress decreases among SEE program participants compared to the control group.
The study hypothesis is that glaucoma patients with poor adherence who receive motivational-interviewing based counseling and personalized education from a trained non-physician glaucoma coach through the SEE Program will improve their medication adherence compared to glaucoma patients standard care enhanced by additional educational handouts.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Percent Electronically Monitored Medication Adherence Over Six Months |
77.6; 58.0 | <0.001 sig |
| PRIMARY Percentage of Participants Who Achieved >= 80% Medication Adherence Over the 6 Month Study Period |
62; 27; 51; 87 | <0.001 sig |
| SECONDARY Change in Glaucoma-related Distress |
2.5; 2.4; 1.9; 2.2; -0.6; -0.2 | — |
Eligibility Criteria
Inclusion Criteria
- Taking greater or equal to 1 ocular hypotensive medication with a diagnosis of any kind of glaucoma, suspected glaucoma or ocular hypertension
- Did not opt-out from recruitment letter
Exclusion Criteria
- Do not speak English
- Have a diagnosed serious mental illness (for example, Schizophrenia)
- Diagnosed cognitive impairment
- Do not instill their own eye drops
- Had laser or incisional glaucoma surgery within three months of enrollment or scheduled during the six-month study period
- Unable to attend all study visits
- Active ocular infection or uveitis
Data sourced from ClinicalTrials.gov (NCT04735653). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.